Transgender hormone therapy

Short description: Gender-affirming medical treatment

Transgender hormone therapy, also called hormone replacement therapy (HRT) or gender-affirming hormone therapy (GAHT), is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity. This form of hormone therapy is given as one of two types, based on whether the goal of treatment is masculinization or feminization:

* Masculinizing hormone therapy – for transgender men or transmasculine people; consists of androgens and antiestrogens.
* Feminizing hormone therapy – for transgender women or transfeminine people; consists of estrogens with or without antiandrogens.

Eligibility for transgender hormone therapy may be concluded by assessing a patient for gender dysphoria or persistent gender incongruence, though many medical institutions now used an informed consent model. This model ensures patients are informed of the procedure process, including possible benefits and risks, while removing many of the historical barriers needed to start hormone therapy. Treatment guidelines for therapy have been developed by several medical associations.

Some intersex people may also undergo hormone therapy, either starting in childhood to confirm the sex they were assigned at birth, or later in order to align their sex with their gender identity. Non-binary people may also engage in hormone therapy in order to achieve a desired balance of sex hormones or to help align their bodies with their gender identities.[1] Many transgender people obtain hormone therapy from a licensed health care provider and others obtain and self-administer hormones.

## Contents

* 1 Requirements
* 1.1 Gender dysphoria
* 2 Treatment options
* 2.1 Guidelines
* 2.2 Delaying puberty in adolescents
* 2.3 Feminizing hormone therapy
* 2.4 Masculinizing hormone therapy
* 3 Safety
* 3.1 Feminizing hormone therapy
* 3.2 Masculinizing hormone therapy
* 3.3 Fertility consideration
* 4 Treatment eligibility
* 4.1 WPATH Standards of Care
* 4.2 Readiness
* 5 Accessibility
* 6 See also
* 7 References

## Requirements

The formal requirements to begin gender-affirming hormone therapy vary widely depending on geographic location and specific institution. Gender affirming hormones can be prescribed by a wide range of medical providers including, but not limited to, primary care physicians, endocrinologists, and obstetrician-gynecologists.[2]

Historically, many health centers required a psychiatric evaluation and/or a letter from a therapist before beginning therapy. Many centers now use an informed consent model that does not require any routine formal psychiatric evaluation but instead focuses on reducing barriers to care by ensuring a person can understand the risks, benefits, alternatives, unknowns, limitations, and risks of no treatment.[3] Some LGBT health organizations (notably Chicago's Howard Brown Health Center[4] and Planned Parenthood[5]) advocate for this type of informed consent model.

The Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People (SOC) require that patients seeking gender-affirmation hormone therapy be evaluated for gender dysphoria by either a mental health professional or hormone provider who is qualified in the area of transgender care. The Standards also require that the patient give informed consent, in other words, that they consent to the treatment after being fully informed of the risks involved.[6] Before beginning gender-affirming hormone therapy, the patient must be evaluated for significant medical and mental health concerns. If present, these must be addressed and reasonably well-controlled.[6]

The World Professional Association for Transgender Health (WPATH) Standards of Care, 7th edition, note that both of these approaches to care are appropriate.[2]

### Gender dysphoria

Many international guidelines and institutions require persistent, well-documented gender dysphoria as a pre-requisite to starting gender-affirmation therapy. Gender dysphoria refers to the psychological discomfort or distress that an individual can experience if their sex assigned at birth is incongruent with that person's gender identity.[6] Signs of gender dysphoria can include comorbid mental health stressors such as depression, anxiety, low self-esteem, and social isolation.[7] Not all gender nonconforming individuals experience gender dysphoria.[8]

## Treatment options

### Guidelines

The World Professional Association for Transgender Health (WPATH) and the Endocrine Society formulated guidelines that created a foundation for health care providers to care for transgender patients.[9] UCSF guidelines are also used.[3] There is no generally agreed-upon set of guidelines, however.[10]

### Delaying puberty in adolescents

Tanner Stages for Female Sexual Characteristics Tanner Stages for Male Sexual Characteristics

Adolescents experiencing gender dysphoria may opt to undergo puberty-suppressing hormone therapy at the onset of puberty. The Standards of Care set forth by WPATH recommend individuals pursuing puberty-suppressing hormone therapy wait until at least experiencing Tanner Stage 2 pubertal development.[6] Tanner Stage 2 is defined by the appearance of scant pubic hair, breast bud development, and/or slight testicular growth.[11] WPATH classifies puberty-suppressing hormone therapy as a "fully reversible" intervention. Delaying puberty allows individuals more time to explore their gender identity before deciding on more permanent interventions and prevents the physical changes associated with puberty.[6]

The preferred puberty-suppressing agent for both individuals assigned male at birth and individuals assigned female at birth is a GnRH Analogue.[6] This approach temporarily shuts down the Hypothalamic-Pituitary-Gonadal (HPG) Axis, which is responsible for the production of hormones (estrogen, testosterone) that cause the development of secondary sexual characteristics in puberty.[12]

### Feminizing hormone therapy

Feminizing hormone therapy is typically used by transgender women, who desire the development of feminine secondary sex characteristics. Individuals who identify as non-binary may also opt-in for feminizing hormone treatment to better align their body with their desired gender expression.[13] Feminizing hormone therapy usually includes medication to suppress testosterone production and induce feminization. Types of medications include estrogens, antiandrogens (testosterone blockers), and progestogens.[14] Most commonly, an estrogen is combined with an antiandrogen to suppress and block testosterone.[15] This allows for demasculinization and promotion of feminization and breast development. Estrogens are administered in various modalities including injection, transdermal patch, and oral tablets.[15]

The desired effects of feminizing hormone therapy focus on the development of feminine secondary sex characteristics. These desired effects include: breast tissue development, redistribution of body fat, decreased body hair, reduction of muscle mass, and more.[15] The table below summarizes some of the effects of feminizing hormone therapy in transgender women:

Effects of feminizing hormone therapy Effect | Time to expected
onset of effect[lower-alpha 1] | Time to expected
maximum effect[lower-alpha 1][lower-alpha 2] | Permanency if hormone
therapy is stopped

|
|
|

Breast development and nipple/areolar enlargement | 2–6 months | 1–5 years | Permanent
Thinning/slowed growth of facial/body hair | 4–12 months | >3 years[lower-alpha 3] | Reversible
Cessation/reversal of male-pattern scalp hair loss | 1–3 months | 1–2 years[lower-alpha 4] | Reversible
Softening of skin/decreased oiliness and acne | 3–6 months | Unknown | Reversible
Redistribution of body fat in a feminine pattern | 3–6 months | 2–5 years | Reversible
Decreased muscle mass/strength | 3–6 months | 1–2 years[lower-alpha 5] | Reversible
Widening and rounding of the pelvis[lower-alpha 6] | Unspecified | Unspecified | Permanent
Changes in mood, emotionality, and behavior | Unspecified | Unspecified | Reversible
Decreased sex drive | 1–3 months | Temporary[16] | Reversible
Decreased spontaneous/morning erections | 1–3 months | 3–6 months | Reversible
Erectile dysfunction and decreased ejaculate volume | 1–3 months | Variable | Reversible
Decreased sperm production/fertility | Unknown | >3 years | Reversible or permanent[lower-alpha 7]
Decreased testicle size | 3–6 months | 2–3 years | Unknown
Decreased penis size | None[lower-alpha 8] | Not applicable | Not applicable
Decreased prostate gland size | Unspecified | Unspecified | Unspecified
Voice changes | None[lower-alpha 9] | Not applicable | Not applicable

Footnotes and sources

Footnotes:

1. ↑ 1.0 1.1 Estimates represent published and unpublished clinical observations.
2. ↑ Time at which further changes are unlikely at maximum maintained dose. Maximum effects vary widely depending on genetics, body habitus, age, and status of gonad removal. Generally, older individuals with intact gonads may have less feminization overall.
3. ↑ Complete removal of male facial and body hair requires electrolysis, laser hair removal, or both. Temporary hair removal can be achieved with shaving, epilating, waxing, and other methods.
4. ↑ Familial scalp hair loss may occur if estrogens are stopped.
5. ↑ Varies significantly depending on the amount of physical exercise.
6. ↑ Occurs only in individuals of pubertal age who have not yet completed epiphyseal closure.
7. ↑ Additional research is needed to determine permanency, but a permanent impact of estrogen therapy on sperm quality is likely and sperm preservation options should be counseled on and considered before initiation of therapy.
8. ↑ Conflicting reports, with none reported observed in transgender women but significant albeit minor reduction of penis size reported in men with prostate cancer on androgen deprivation therapy.[17][18][19][20]
9. ↑ Treatment by speech pathologists for voice training is effective.

Sources: Guidelines:[21][6][22] Reviews/book chapters: [23][24][25][26] Studies:[27][28]

### Masculinizing hormone therapy

Main article: Medicine:Masculinizing hormone therapy

Masculinizing hormone therapy is typically used by transgender men, who desire the development of masculine secondary sex characteristics. Masculinizing hormone therapy usually includes testosterone to produce masculinization and suppress the production of estrogen.[29] Treatment options include oral, parenteral, subcutaneous implant, and transdermal (patches, gels). Dosing is patient-specific and is discussed with the physician.[30] The most commonly prescribed methods are intramuscular and subcutaneous injections. This dosing can be weekly or biweekly depending on the individual patient.[citation needed]

Unlike feminizing hormone therapy, individuals undergoing masculinizing hormone therapy do not usually require additional hormone suppression such as estrogen suppression. Therapeutic doses of testosterone are usually sufficient to inhibit the production of estrogen to desired physiologic levels.[12]

The desired effects of masculinizing hormone therapy focus on the development of masculine secondary sex characteristics. These desired effects include: increased muscle mass, development of facial hair, voice deepening, increase and thickening of body hair, and more.[31]

Effects of masculinizing hormone therapy[3][6] Reversible Changes  | Irreversible Changes

|

Increased libido  | Deepening of voice
Redistribution of body fat  | Growth of facial/body hair
Cessation of ovulation/menstruation  | Male-pattern baldness
Increased muscle mass  | Enlargement of clitoris
Increased perspiration  | Growth spurt/closure of growth plates
Acne  | Breast atrophy
Increased RBC count  |

## Safety

Hormone therapy for transgender individuals has been shown in medical literature to be generally safe, when supervised by a qualified medical professional.[32] There are potential risks with hormone treatment that will be monitored through screenings and lab tests such as blood count (hemoglobin), kidney and liver function, blood sugar, potassium, and cholesterol.[30][14] Taking more medication than directed may lead to health problems such as increased risk of cancer, heart attack from thickening of the blood, blood clots, and elevated cholesterol.[30][33]

### Feminizing hormone therapy

The Standards of Care published by the World Professional Association for Transgender Health (WPATH) summarize many of the risks associated with feminizing hormone therapy (outlined below).[6] For more in-depth information on the safety profile of estrogen-based feminizing hormone therapy visit the feminizing hormone therapy page.

Likely Increased Risk  | Possible Increased Risk  | Inconclusive/No Increased Risk

|
|

Venous thromboembolic disease  | Type 2 diabetes | Breast cancer
Cardiovascular disease | Hypertension | Prostate cancer
Hypertriglyceridemia  | Hyperprolactinaemia |
Gallstones | Osteoporosis |
Hyperkalemia |  |
Cerebrovascular disease  |  |
Polyuria (or dehydration)[lower-alpha 1] |  |
Meningioma[lower-alpha 2] |  |

1. ↑ Only present in individuals taking spironolactone
2. ↑ Only present in individuals taking cyproterone

### Masculinizing hormone therapy

The Standards of Care published by the World Professional Association for Transgender Health (WPATH) summarize many of the risks associated with masculinizing hormone therapy (outlined below).[6] For more in-depth information on the safety profile of testosterone-based masculinizing hormone therapy visit the masculinizing hormone therapy page.

Summary of Risks of Testosterone Therapy[34] Likely Increased Risk  | Possible Increased Risk  | Inconclusive/No Increased Risk

|
|

Polycythemia  | Type 2 diabetes | Osteoporosis
Weight gain  |  | Breast cancer
Acne |  | Ovarian cancer
Pattern hair loss |  | Uterine cancer
Hypertension |  | Cervical cancer
Sleep apnea |  |
Decreased HDL cholesterol |  |
Decreased LDL cholesterol |  |
Cardiovascular disease |  |
Hypertriglyceridemia  |  |

### Fertility consideration

Transgender hormone therapy may limit fertility potential.[35] Should a transgender individual choose to undergo sex reassignment surgery, their fertility potential is lost completely.[36] Before starting any treatment, individuals may consider fertility issues and fertility preservation. Options include semen cryopreservation, oocyte cryopreservation, and ovarian tissue cryopreservation.[35][36]

A study presented at ENDO 2019 (the Endocrine Society's conference) shows that even after one year of treatment with testosterone, a transgender man can preserve his fertility potential.[37]

## Treatment eligibility

Many providers use informed consent, whereby someone seeking hormone therapy can sign a statement of informed consent and begin treatment without much gatekeeping. For other providers, eligibility is determined using major diagnostic tools such as ICD-11 or the Diagnostic and Statistical Manual of Mental Disorders (DSM) to classify a patient with gender dysphoria. Psychiatric conditions can commonly accompany or present similar to gender incongruence and gender dysphoria. For this reason, patients are assessed using DSM-5 criteria or ICD-11 criteria in addition to screening for psychiatric disorders. The Endocrine Society requires physicians that diagnose gender dysphoria and gender incongruence to be trained in psychiatric disorders with competency in ICD-11 and DSM-5. The healthcare provider should also obtain a thorough assessment of the patient's mental health and identify potential psychosocial factors that can affect therapy.[38]

### WPATH Standards of Care

The WPATH Standards of Care, most recently published in 2022, outlines a series of guidelines which should be met before a patient should be allowed transgender hormone replacement therapy:[34]

* Gender incongruence is marked and sustained
* Patient meets diagnostic criteria for gender incongruence prior to gender-affirming hormone treatment in regions where a diagnosis is necessary to access health care
* Patient has capacity to consent to hormone therapy treatment
* Other possible causes of apparent gender incongruence have been identified and excluded
* Mental health and physical conditions that could negatively impact the outcome of treatment have been assessed
* Understands the effect of gender-affirming hormone treatment on reproduction and they have explored reproductive options

### Readiness

Some organizations – but fewer than in the past – require that patients spend a certain period of time living in their desired gender role before starting hormone therapy. This period is sometimes called real-life experience (RLE). The Endocrine Society stated in 2009 that individuals should either have a documented three months of RLE or undergo psychotherapy for a period of time specified by their mental health provider, usually a minimum of three months.[39]

Transgender and gender non-conforming activists, such as Kate Bornstein, have asserted that RLE is psychologically harmful and is a form of "gatekeeping", effectively barring individuals from transitioning for as long as possible, if not permanently.[40]

## Accessibility

Gender-affirming care is health care that affirms people to live authentically in their genders, no matter the gender they were assigned at birth or the path their gender affirmation (or transition) takes. It allows each person to seek only the changes or medical interventions they desire to affirm their own gender identity, and hormone therapy ("HRT" or gender-affirming hormone therapy) may be a part of that.[41]

Some transgender people choose to self-administer hormone replacement medications, often because doctors have too little experience in this area, or because no doctor is available. Others self-administer because their doctor will not prescribe hormones without a letter from a psychotherapist stating that the patient meets the diagnostic criteria and is making an informed decision to transition. Many therapists require at least three months of continuous psychotherapy and/or real-life experience before they will write such a letter. Because many individuals must pay for evaluation and care out-of-pocket, costs can be prohibitive.[citation needed]

Access to medication can be poor even where health care is provided free. In a patient survey conducted by the United Kingdom 's National Health Service in 2008, 5% of respondents acknowledged resorting to self-medication, and 46% were dissatisfied with the amount of time it took to receive hormone therapy. The report concluded in part: "The NHS must provide a service that is easy to access so that vulnerable patients do not feel forced to turn to DIY remedies such as buying drugs online with all the risks that entails. Patients must be able to access professional help and advice so that they can make informed decisions about their care, whether they wish to take the NHS or private route without putting their health and indeed their lives in danger."[42] Self-administration of hormone replacement medications without medical supervision may have untoward health effects and risks.[43]

A number of private companies have attempted to increase accessibility for hormone replacement medications and help transgender people navigate the complexities of access to treatment.[citation needed]

## See also

* Hormone therapy
* Sex reassignment surgery
* Real-life experience (transgender)

## References

1. ↑ "What It Means to Transition When You're Non-Binary". Teen Vogue. November 30, 2017. https://www.teenvogue.com/story/non-binary-transitioning.
2. ↑ 2.0 2.1 "Updated recommendations from the world professional association for transgender health standards of care". American Family Physician 87 (2): 89–93. January 2013. PMID 23317072.
3. ↑ 3.0 3.1 3.2 Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People (2nd ed.). San Francisco, CA: UCSF Transgender Care, Department of Family and Community Medicine, University of California San Francisco.. June 2016. https://transcare.ucsf.edu/guidelines.
4. ↑ "Howard Brown Health Center Establishes Transgender Hormone Protocol". www.howardbrown.org. Howard Brown. http://www.howardbrown.org/hb_news.asp?id=1228.
5. ↑ "What Health Care & Services Do Transgender People Require?". https://www.plannedparenthood.org/learn/sexual-orientation-gender/trans-and-gender-nonconforming-identities/what-do-i-need-know-about-trans-health-care.
6. ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 "Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7". International Journal of Transgenderism 13 (4): 165–232. August 2012. doi:10.1080/15532739.2011.700873.
7. ↑ "Gender dysphoria" (in en). 2017-10-23. https://www.nhs.uk/conditions/gender-dysphoria/.
8. ↑ "Research priorities for gender nonconforming/transgender youth: gender identity development and biopsychosocial outcomes". Current Opinion in Endocrinology, Diabetes, and Obesity 23 (2): 172–179. April 2016. doi:10.1097/MED.0000000000000236. PMID 26825472.
9. ↑ "Hormone therapy for transgender patients". Translational Andrology and Urology 5 (6): 877–884. December 2016. doi:10.21037/tau.2016.09.04. PMID 28078219.
10. ↑ Houssayni, Sarah; Nilsen, Kari (Feb 28, 2018). "Transgender Competent Provider: Identifying Transgender Health Needs, Health Disparities, and Health Coverage". Kansas Journal of Medicine 11 (1): 15–19. doi:10.17161/kjm.v11i1.8679. PMID 29844850.
11. ↑ "Tanner Stages". StatPearls. Treasure Island (FL): StatPearls Publishin. 2021. http://www.ncbi.nlm.nih.gov/books/NBK470280/. Retrieved 2021-11-12.
12. ↑ 12.0 12.1 "Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium" (in english). Hormone Research in Paediatrics 91 (6): 357–372. 2019. doi:10.1159/000501336. PMID 31319416.
13. ↑ "Hormone Use for Non-Binary People". GenderGP. https://www.gendergp.com/non-binary-hormone-use/.
14. ↑ 14.0 14.1 "Information on Estrogen Hormone Therapy". Transgender Care. transcare.ucsf.edu. https://www.gendergp.com/non-binary-hormone-use/.
15. ↑ 15.0 15.1 15.2 "Overview of feminizing hormone therapy". Gender Affirming Health Program. transcare.ucsf.edu. https://transcare.ucsf.edu/guidelines/feminizing-hormone-therapy.
16. ↑ "Sexual Desire Changes in Transgender Individuals Upon Initiation of Hormone Treatment: Results From the Longitudinal European Network for the Investigation of Gender Incongruence". The Journal of Sexual Medicine 17 (4): 812–825. April 2020. doi:10.1016/j.jsxm.2019.12.020. PMID 32008926. https://pubmed.ncbi.nlm.nih.gov/32008926/.
17. ↑ "Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life". The Journal of Sexual Medicine 7 (9): 2996–3010. September 2010. doi:10.1111/j.1743-6109.2010.01902.x. PMID 20626600.
18. ↑ "Side effects of androgen deprivation therapy: monitoring and minimizing toxicity". Urology 61 (2 Suppl 1): 32–38. February 2003. doi:10.1016/S0090-4295(02)02397-X. PMID 12667885.
19. ↑ "Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer". Journal of Clinical Oncology 30 (30): 3720–3725. October 2012. doi:10.1200/JCO.2012.41.8509. PMID 23008326.
20. ↑ Andrology: Male Reproductive Health and Dysfunction. Springer Science & Business Media. 29 June 2013. pp. 54–. ISBN 978-3-662-04491-9. https://books.google.com/books?id=05fsCAAAQBAJ&pg=PA54.
21. ↑ "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline". The Journal of Clinical Endocrinology and Metabolism 102 (11): 3869–3903. November 2017. doi:10.1210/jc.2017-01658. PMID 28945902.
22. ↑ "Guidelines and Protocols for Comprehensive Primary Care for Trans Clients". Sherbourne Health Centre. 2015. http://sherbourne.on.ca/wp-content/uploads/2014/02/Guidelines-and-Protocols-for-Comprehensive-Primary-Care-for-Trans-Clients-2015.pdf.
23. ↑ "Cross-sex hormone therapy for gender dysphoria". Journal of Endocrinological Investigation 38 (3): 269–282. March 2015. doi:10.1007/s40618-014-0186-2. PMID 25403429.
24. ↑ "Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects". The Journal of Clinical Endocrinology and Metabolism 88 (8): 3467–3473. August 2003. doi:10.1210/jc.2002-021967. PMID 12915619.
25. ↑ "Hormone Treatment in Transsexuals". Journal of Psychology & Human Sexuality 5 (4): 39–54. 1993. doi:10.1300/J056v05n04_03. ISSN 0890-7064.
26. ↑ "Endocrine intervention for transsexuals". Clinical Endocrinology 59 (4): 409–418. October 2003. doi:10.1046/j.1365-2265.2003.01821.x. PMID 14510900.
27. ↑ "Breast development in male-to-female transgender patients after one year cross-sex hormonal treatment". Endocrine Abstracts. 2016. doi:10.1530/endoabs.41.GP146. ISSN 1479-6848.
28. ↑ "Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study". The Journal of Clinical Endocrinology and Metabolism 103 (2): 532–538. February 2018. doi:10.1210/jc.2017-01927. PMID 29165635.
29. ↑ "Masculinizing hormone therapy - Mayo Clinic". https://www.mayoclinic.org/tests-procedures/ftm-hormone-therapy/about/pac-20385099.
30. ↑ 30.0 30.1 30.2 "Information on Testosterone Hormone Therapy". Transgender Care. transcare.ucsf.edu. https://transcare.ucsf.edu/article/information-testosterone-hormone-therapy.
31. ↑ "Overview of masculinizing hormone therapy". UCSF Gender Affirming Health Program. San Francisco, CA: The University of California. 17 June 2016. https://transcare.ucsf.edu/guidelines/masculinizing-therapy.
32. ↑ "Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals". Journal of Clinical & Translational Endocrinology 2 (2): 55–60. June 2015. doi:10.1016/j.jcte.2015.02.003. PMID 28090436.
33. ↑ "A randomized, double-blind study of two combined oral contraceptives containing the same progestogen, but different estrogens. World Health Organization Task Force on Oral Contraception". Contraception 21 (5): 445–459. May 1980. doi:10.1016/0010-7824(80)90010-4. PMID 7428356.
34. ↑ 34.0 34.1 Cite error: Invalid `<ref>` tag; no text was provided for refs named `:0`
35. ↑ 35.0 35.1 "Transgenderism and reproduction". Current Opinion in Endocrinology, Diabetes, and Obesity 20 (6): 575–579. December 2013. doi:10.1097/01.med.0000436184.42554.b7. PMID 24468761.
36. ↑ 36.0 36.1 "Gender reassignment and assisted reproduction: present and future reproductive options for transsexual people". Human Reproduction 16 (4): 612–614. April 2001. doi:10.1093/humrep/16.4.612. PMID 11278204.
37. ↑ "Ovary function is preserved in transgender men at one year of testosterone therapy". Endocrine Society. 23 March 2019. https://www.endocrine.org/news-and-advocacy/news-room/2019/endo-2019--ovary-function-is-preserved-in-transgender-men-at-one-year-of-testosterone-therapy.
38. ↑ "CORRIGENDUM FOR "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline"". The Journal of Clinical Endocrinology and Metabolism 103 (7): 2758–2759. July 2018. doi:10.1210/jc.2018-01268. PMID 29905821.
39. ↑ "Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline". The Journal of Clinical Endocrinology and Metabolism 94 (9): 3132–3154. September 2009. doi:10.1210/jc.2009-0345. PMID 19509099.
40. ↑ Bornstein, Kate (2013). My Gender Workbook, Updated : How to Become a Real Man, a Real Woman, the Real You, or Something Else Entirely. (2nd ed.). New York: Routledge. ISBN 978-0415538657.
41. ↑ "Gender-Affirming Hormone Therapy 101: Introducing the #HRTSavesLives Campaign". 10 August 2020. https://getplume.co/blog/plume-day-campaign/.
42. ↑ "Survey of Patient Satisfaction with Transgender Services". The Audit Information & Analysis Unit. National Health Service. http://www.gires.org.uk/assets/Medpro-Assets/AIAUSatisfactionAuditJune2008.pdf.
43. ↑ "[Morbidity in transsexual patients with cross-gender hormone self-treatment"] (in es). Medicina Clinica 113 (13): 484–487. October 1999. PMID 10604171. https://www.saludtrans.cl/wp-content/uploads/2012/10/morbilidad-automedicacic3b3n-en-transexuales.pdf. Retrieved 2018-11-11.

* v
* t
* e

Pharmacological body alteration

* Bodybuilding supplement
* Breast enlargement
* Clitoris enlargement
* Ergogenic use of anabolic steroids
* Growth hormone therapy
* Transgender hormone therapy
* Feminizing hormone therapy
* Masculinizing hormone therapy
* Penis enlargement
* Performance-enhancing substance

{{Navbox

| name = Androgens and antiandrogens
| title = Androgens and antiandrogens
| state = collapsed
| listclass = hlist
| groupstyle = text-align:center;

| group1 = Androgens
(incl. AAS)

| list1 =

AR agonists|

* Testosterone derivatives: Androstenediol dipropionate
* Boldenone undecylenate
* Clostebol
* Clostebol acetate
* Clostebol caproate
* Clostebol propionate
* Cloxotestosterone acetate
* Prasterone (dehydroepiandrosterone, DHEA)
* Prasterone enanthate (DHEA enanthate)
* Prasterone sulfate (DHEA sulfate)
* Quinbolone
* Testosterone#
* Testosterone esters (e.g., testosterone cypionate, testosterone enanthate]], testosterone propionate]], testosterone undecanoate]], testosterone ester mixture]]s (Deposterona, Omnadren, Sustanon, Testoviron Depot))

* Dihydrotestosterone derivatives: Androstanolone (stanolone, dihydrotestosterone, DHT)
* Androstanolone esters
* Bolazine capronate
* Drostanolone propionate (dromostanolone propionate)
* Epitiostanol
* Mepitiostane
* Mesterolone
* Metenolone acetate (methenolone acetate)
* Metenolone enanthate (methenolone enanthate)
* Stenbolone acetate

* 19-Nortestosterone derivatives: Bolandiol dipropionate
* Nandrolone esters (e.g., nandrolone decanoate, nandrolone phenylpropionate)
* Norclostebol
* Norclostebol acetate
* Oxabolone cipionate (oxabolone cypionate)
* Trenbolone acetate
* Trenbolone hexahydrobenzylcarbonate (trenbolone cyclohexylmethylcarbonate)

* 17α-Alkylated testosterone derivatives: Bolasterone
* Calusterone
* Chlorodehydromethyltestosterone (CDMT)
* Fluoxymesterone
* Formebolone
* Metandienone (methandienone, methandrostenolone)
* Methandriol (methylandrostenediol)
* Methandriol bisenanthoyl acetate
* Methandriol dipropionate
* Methandriol propionate
* Methyltestosterone
* Methyltestosterone 3-hexyl ether
* Oxymesterone
* Penmesterol
* Tiomesterone (thiomesterone)

* 17α-Alkylated dihydrotestosterone derivatives: Androisoxazole
* Furazabol
* Mebolazine (dimethazine)
* Mestanolone
* Oxandrolone
* Oxymetholone
* Stanozolol

* 17α-Alkylated 19-nortestosterone derivatives: Ethylestrenol
* Mibolerone
* Norethandrolone
* Normethandrone (methylestrenolone, normethisterone)
* Propetandrol (propethandrol)

* 17α-Vinyltestosterone derivatives: Norvinisterone (vinylnortestosterone)

* 17α-Ethynyltestosterone derivatives: Danazol
* Gestrinone
* Progestins (e.g., ethisterone (ethynyltestosterone), levonorgestrel, norgestrel, norethisterone (norethindrone), [[Chemistry:Lynestrlynestrenol, Norgestrienone|norgestrienone]])
* Tibolone

* Progesterone derivatives: Medroxyprogesterone acetate

|

Progonadotropins|

* Antiestrogens (e.g., tamoxifen, Chemistry:Clomifene

| group2 = Antiandrogens
| list2 = {{Navbox|child
| groupstyle = text-align:center;
| groupwidth = 9em;

| group1 = AR antagonists
| list1 =

* Steroidal: Abiraterone acetate
* Canrenone
* Chlormadinone acetate
* Cyproterone acetate
* Delmadinone acetate
* Dienogest
* Drospirenone
* Medrogestone
* Megestrol acetate
* Nomegestrol acetate
* Osaterone acetate
* Oxendolone
* Potassium canrenoate
* Spironolactone

* Nonsteroidal: Apalutamide
* Bicalutamide
* Cimetidine
* Darolutamide
* Enzalutamide
* Flutamide
* Ketoconazole
* Nilutamide
* Seviteronel†
* Topilutamide (fluridil)

| group2 = Steroidogenesis
inhibitors

| list2 =

5α-Reductase|

* Alfatradiol
* Dutasteride
* Epristeride
* Finasteride
* Saw palmetto extract

|

Others|

* Abiraterone acetate
* Aminoglutethimide
* Bifluranol
* Cyproterone acetate
* Flutamide
* Ketoconazole
* Nilutamide
* Seviteronel†
* Spironolactone

| group3 = Antigonadotropins
| list3 =

* D2 receptor antagonists (prolactin releasers) (e.g., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, sulpiride)
* Estrogens (e.g., bifluranol, [[diethylstilbestrol, estradiol, estradiol esters, ethinylestradiol, ethinylestradiol sulfonate, paroxypropione)
* GnRH agonists (e.g., leuprorelin)
* GnRH antagonists (e.g., cetrorelix)
* Progestogens (incl., chlormadinone acetate, [[cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, [[Chemistry:Medroxyprogesterone medroxyprogesterone acetate, Chemistry:Megestrol acetate|megestrol acetate]])

| group4 = Others
| list4 =

* Androstenedione immunogens: Androvax (androstenedione albumin)
* Ovandrotone albumin (Fecundin)

| liststyle = background:#DDDDFF;

| list3 =

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

See also
Androgen receptor modulators
Estrogens and antiestrogens
Progestogens and antiprogestogens
List of androgens/anabolic steroids

* v
* t
* e

Estrogens and antiestrogens

Estrogens|

| ER agonists|

* Steroidal: Alfatradiol
* Certain androgens/anabolic steroids (e.g., testosterone, testosterone esters, methyltestosterone, metandienone, nandrolone esters) (via estrogenic metabolites)
* Certain progestins (e.g., norethisterone, noretynodrel, etynodiol diacetate]], tibolone)
* Clomestrone
* Cloxestradiol acetate
* Conjugated estriol
* Conjugated estrogens
* Epiestriol
* Epimestrol
* Esterified estrogens
* Estetrol†
* Estradiol
* Estradiol esters (e.g., estradiol acetate, estradiol benzoate, estradiol cypionate, estradiol enanthate, estradiol undecylate, [[Chemistry:Estradiol estradiol valerate, Polyestradiol phosphate|polyestradiol phosphate]], estradiol ester mixtures (Climacteron))
* Estramustine phosphate
* Estriol
* Estriol esters (e.g., estriol succinate, polyestriol phosphate)
* Estrone
* Estrone esters
* Estrone sulfate
* Estropipate (piperazine estrone sulfate)
* Ethinylestradiol#
* Ethinylestradiol sulfonate
* Hydroxyestrone diacetate
* Mestranol
* Methylestradiol
* Moxestrol
* Nilestriol
* Prasterone (dehydroepiandrosterone; DHEA)
* Prasterone enanthate
* Prasterone sulfate
* Promestriene
* Quinestradol
* Quinestrol

* Nonsteroidal: Benzestrol
* Bifluranol
* Chlorotrianisene
* Dienestrol
* Dienestrol diacetate
* Diethylstilbestrol (stilbestrol)
* Diethylstilbestrol esters/ethers
* Dimestrol (diethylstilbestrol dimethyl ether)
* Fosfestrol (diethylstilbestrol diphosphate)
* Mestilbol (diethylstilbestrol monomethyl ether)
* Doisynoestrol (fenocycline)
* Hexestrol
* Hexestrol esters
* Methallenestril
* Methestrol dipropionate (promethestrol dipropionate)
* Paroxypropione
* Quadrosilan
* Triphenylbromoethylene
* Triphenylchloroethylene
* Zeranol

|

Progonadotropins|

* Antiandrogens (e.g., bicalutamide)
* GnRH agonists (e.g., GnRH (gonadorelin), leuprorelin)
* Gonadotropins (e.g., FSH, LH)

Antiestrogens|

| ER antagonists
(incl. SERMs/SERDs)|

* Acolbifene†
* Anordrin
* Bazedoxifene
* Broparestrol
* Clomifene#
* Cyclofenil
* Enclomifene†
* Epitiostanol
* Lasofoxifene
* Mepitiostane
* Ormeloxifene
* Ospemifene
* Raloxifene
* Tamoxifen#
* Toremifene

* Exclusively antagonistic: Fulvestrant

|

Aromatase inhibitors|

* First-generation: Aminoglutethimide
* Testolactone

* Second-generation: Fadrozole
* Formestane

* Third-generation: Anastrozole
* Exemestane
* Letrozole

Antigonadotropins|

* Androgens/Anabolic steroid|Anabolic steroid|Anabolic steroid]]]]s (e.g., testosterone, testosterone esters, nandrolone esters, oxandrolone, fluoxymesterone)
* D2 receptor antagonists (prolactin releasers) (e.g., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, sulpiride)
* GnRH agonists (e.g., leuprorelin, goserelin)
* GnRH antagonists (e.g., cetrorelix, elagolix)
* Progestogens (e.g., chlormadinone acetate, cyproterone acetate, gestonorone caproate, hydroxyprogesterone caproate, [[Chemistry:Medroxyprogesterone medroxyprogesterone acetate, Chemistry:Megestrol acetate|megestrol acetate]])

Others|

* Mixed mechanism of action: Danazol
* Gestrinone

* Androstenedione immunogens: Androvax (androstenedione albumin)
* Ovandrotone albumin (Fecundin)

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

See also
Estrogen receptor modulators
Androgens and antiandrogens
Progestogens and antiprogestogens
List of estrogens

* v
* t
* e

Progestogens and antiprogestogens

Progestogens
(and progestins)|

| PR agonists|

* Progesterone derivatives: Progesterone
* Quingestrone

* Retroprogesterone derivatives: Dydrogesterone
* Trengestone

* 17α-Hydroxyprogesterone (and closely related) derivatives: 17α-Hydroxylated: Acetomepregenol (mepregenol diacetate)
* Algestone acetophenide (dihydroxyprogesterone acetophenide)
* Anagestone acetate
* Chlormadinone acetate
* Chlormethenmadinone acetate
* Cyproterone acetate
* Delmadinone acetate
* Flugestone acetate (flurogestone acetate)
* Flumedroxone acetate
* Hydroxyprogesterone acetate
* Hydroxyprogesterone caproate
* Hydroxyprogesterone heptanoate
* Medroxyprogesterone acetate#
* Megestrol acetate
* Melengestrol acetate
* Methenmadinone acetate
* Osaterone acetate
* Pentagestrone acetate
* Proligestone; 17α-Methylated: Medrogestone; Others: Haloprogesterone

* 19-Norprogesterone derivatives: 17α-Hydroxylated: Gestonorone caproate (gestronol hexanoate)
* Nomegestrol acetate
* Norgestomet
* Segesterone acetate (nestorone, elcometrine); 17α-Methylated: Demegestone
* Promegestone
* Trimegestone

* Testosterone derivatives: Estranes: Danazol
* Dimethisterone
* Ethisterone

* 19-Nortestosterone derivatives: Estranes: Allylestrenol
* Altrenogest
* Dienogest
* Etynodiol diacetate
* Lynestrenol
* Norethisterone (norethindrone)#
* Norethisterone acetate
* Norethisterone enanthate
* Noretynodrel
* Norgesterone
* Norgestrienone
* Normethandrone (methylestrenolone)
* Norvinisterone
* Oxendolone
* Quingestanol acetate
* Tibolone; Gonanes: Desogestrel
* Etonogestrel
* Gestodene
* Gestrinone
* Levonorgestrel#
* Norelgestromin
* Norgestimate
* Norgestrel

* Spirolactone derivatives: Drospirenone

* Others: Anabolic–androgenic steroids (e.g., nandrolone and esters, trenbolone and esters, ethylestrenol, norethandrolone, others)

|

Antiprogestogens|

| SPRMs|

* Telapristone§
* Ulipristal acetate

|

PR antagonists|

* Aglepristone
* Mifepristone

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

See also
Progesterone receptor modulators
Androgens and antiandrogens
Estrogens and antiestrogens
List of progestogens

* v
* t
* e

GnRH and gonadotropins

GnRH modulators
(incl. analogues)|

| Agonists|

* Peptide: Azagly-nafarelin
* Buserelin
* Deslorelin
* Fertirelin
* Gonadorelin
* Goserelin
* Histrelin
* Lecirelin
* Leuprorelin (leuprolide)
* Nafarelin
* Peforelin
* Triptorelin

|

Antagonists|

* Peptide: Abarelix
* Cetrorelix
* Degarelix
* Ganirelix

* Non-peptide: Elagolix
* Linzagolix†
* Relugolix†

Gonadotropins|

| Preparations|

* Follicle-stimulating hormone
* Human chorionic gonadotropin
* Luteinizing hormone
* Menotropin
* Urofollitropin

|

Others
(indirect)|

| Progonadotropins|

* Sex steroid antagonists (via disinhibition of the HPG axis): Antiandrogens (e.g., flutamide, bicalutamide, enzalutamide)
* Antiestrogens/SERMs (e.g., tamoxifen, Chemistry:Clomifene

|

Antigonadotropins|

* Sex steroid agonists (via negative feedback on the HPG axis): Androgens/anabolic steroids (e.g., testosterone, nandrolone esters, oxandrolone)
* D2 receptor antagonists (prolactin releasers) (incl., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, sulpiride)
* Estrogens (incl., bifluranol, estradiol, estradiol esters, ethinylestradiol, diethylstilbestrol, paroxypropione)
* Progestogen|Progestogens (incl. progestins, e.g., Chemistry:Chlormadinone acetate

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

See also
GnRH and gonadotropin receptor modulators
Androgens and antiandrogens
Estrogens and antiestrogens
Progestogens and antiprogestogens

0.00

(0 votes)

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Transgender_hormone_therapy&oldid=3906220"
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template
*[AAS]: anabolic–androgenic steroid
*[AR]: Androgen receptor
*[ER]: Estrogen receptor
*[GnRH]: gonadotropin-releasing hormone
*[FSH]: follicle-stimulating hormone
*[LH]: luteinizing hormone
*[SERMs]: Selective estrogen receptor modulators
*[SERDs]: selective estrogen receptor downregulators
*[PR]: Progesterone receptor
*[SPRMs]: Selective progesterone receptor modulators
*[HPG]: hypothalamic–pituitary–gonadal